Stock AnalizArdent Health, Inc. ARDT
Hospital/Nursing Management · IPO 2024 · data as of November 13, 2026
Ardent Health, Inc. (ARDT) is a healthcare company listed in the US with a market value of about $2.5B. In the twelve months to September 30, 2026 it had revenue of $6.5B and net income of $146M, a net margin of 2.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 17.3, a price to free cash flow of 8.9, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 6% above the current price.
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $6.5B | $6.3B | $6.0B | $5.4B | $5.1B |
| Net income | $146M | $136M | $210M | $54M | $189M |
| Free cash flow | $282M | $259M | $128M | $84M | -$189M |
| EPS (diluted) | $1.03 | $0.96 | $1.58 | $0.43 | $1.50 |
| Net margin | 2.3% | 2.1% | 3.5% | 1.0% | 3.7% |
| ROIC | — | 6.3% | 8.7% | 6.8% | 25.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $16.62, 7% below the current price; targets range from $12.00 to $21.00; the consensus rating is “Buy”; expected EPS is $1.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Ardent Health’s P/E ratio?
About 17.3, based on the last twelve months of diluted earnings per share (forward P/E about 12.6).
Is Ardent Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 6% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ardent Health pay a dividend?
Not currently.
Is Ardent Health a good stock to buy?
We do not give buy or sell advice. Ardent Health scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.